RDEA119
Information
- Drug Name
- RDEA119
- Description
- Entry(CIViC)
CIViC
[No Data.]
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| RDEA119 is an allosteric MEK inhibitor. Melanoma c... | MAP2K7 | MAP2K7 EXPRESSION | Sensitivity | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00610194 | Completed | Phase 1 | Phase 1 Dose-escalation PK/PD Trial in Advanced Cancer Patients | November 28, 2007 | August 1, 2012 |
| NCT00785226 | Completed | Phase 1/Phase 2 | RDEA119 and Sorafenib Combination Dose Escalation Study | November 2008 | April 2012 |